|
1
|
Kovács Z, Brunner B and Ari C: Beneficial
effects of exogenous ketogenic supplements on aging processes and
age-related neurodegenerative diseases. Nutrients.
13(2197)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Jensen L, Monnat SM, Green JJ, Hunter LM
and Sliwinski MJ: Rural population health and aging: Toward a
multilevel and multidimensional research agenda for the 2020s. Am J
Public Health. 110:1328–1331. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Li Y, Xu H, Wang H, Yang K, Luan J and
Wang S: TREM2: Potential therapeutic targeting of microglia for
Alzheimer's disease. Biomed Pharmacother.
165(115218)2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Maria C and Rauter AP: Nucleoside
analogues: N-glycosylation methodologies, synthesis of antiviral
and antitumor drugs and potential against drug-resistant bacteria
and Alzheimer's disease. Carbohydr Res. 532(108889)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Stocker H, Trares K, Beyer L, Perna L,
Rujescu D, Holleczek B, Beyreuther K, Gerwert K, Schöttker B and
Brenner H: Alzheimer's polygenic risk scores, APOE, Alzheimer's
disease risk, and dementia-related blood biomarker levels in a
population-based cohort study followed over 17 years. Alzheimers
Res Ther. 15(129)2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Weller J and Budson A: Current
understanding of Alzheimer's disease diagnosis and treatment.
F1000Res 7: F1000 Faculty Rev-1161, 2018.
|
|
7
|
Ismail Z, Leon R, Creese B, Ballard C,
Robert P and Smith EE: Optimizing detection of Alzheimer's disease
in mild cognitive impairment: A 4-year biomarker study of mild
behavioral impairment in ADNI and MEMENTO. Mol Neurodegener.
18(50)2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Antoniou A, Stavrou M, Evripidou N,
Georgiou E, Kousiappa I, Koupparis A, Papacostas SS, Kleopa KA and
Damianou C: FUS-mediated blood-brain barrier disruption for
delivering anti-Aβ antibodies in 5XFAD Alzheimer's disease mice. J
Ultrasound: Jul 29, 2023 (Epub ahead of print). doi:
10.1007/s40477-023-00805-4.
|
|
9
|
Śliwińska S and Jeziorek M: The role of
nutrition in Alzheimer's disease. Rocz Panstw Zakl Hig. 72:29–39.
2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fan R, Peng X, Xie L, Dong K, Ma D, Xu W,
Shi X, Zhang S, Chen J, Yu X, et al: Importance of Bmal1 in
Alzheimer's disease and associated aging-related diseases.
Mechanisms and interventions. Aging Cell. 21(e13704)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Carvalho C and Moreira PI: Metabolic
defects shared by Alzheimer's disease and diabetes: A focus on
mitochondria. Curr Opin Neurobiol. 79(102694)2023.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nguyen TT, Ta QTH, Nguyen TKO, Nguyen TTD
and Giau VV: Type 3 diabetes and its role implications in
Alzheimer's disease. Int J Mol Sci. 21(3165)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Janoutová J, Machaczka O, Zatloukalová A
and Janout V: Is Alzheimer's disease a type 3 diabetes? A review.
Cent Eur J Public Health. 30:139–143. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kandimalla R, Thirumala V and Reddy PH: Is
Alzheimer's disease a type 3 diabetes? A critical appraisal.
Biochim Biophys Acta Mol Basis Dis. 1863:1078–1089. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Michailidis M, Moraitou D, Tata DA,
Kalinderi K, Papamitsou T and Papaliagkas V: Alzheimer's disease as
type 3 diabetes: Common pathophysiological mechanisms between
Alzheimer's disease and type 2 diabetes. Int J Mol Sci.
23(2687)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Diniz Pereira J, Gomes Fraga V, Morais
Santos AL, Carvalho MDG, Caramelli P and Braga Gomes K: Alzheimer's
disease and type 2 diabetes mellitus: A systematic review of
proteomic studies. J Neurochem. 156:753–776. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Arnold SE, Arvanitakis Z, Macauley-Rambach
SL, Koenig AM, Wang HY, Ahima RS, Craft S, Gandy S, Buettner C,
Stoeckel LE, et al: Brain insulin resistance in type 2 diabetes and
Alzheimer disease: Concepts and conundrums. Nat Rev Neurol.
14:168–181. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hamzé R, Delangre E, Tolu S, Moreau M,
Janel N, Bailbé D and Movassat J: Type 2 diabetes mellitus and
Alzheimer's disease: Shared molecular mechanisms and potential
common therapeutic targets. Int J Mol Sci. 23(15287)2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chen Z and Zhong C: Decoding Alzheimer's
disease from perturbed cerebral glucose metabolism: Implications
for diagnostic and therapeutic strategies. Prog Neurobiol.
108:21–43. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Candasamy M, Mohamed Elhassan SA, Kumar
Bhattamisra S, Hua WY, Sern LM, Binti Busthamin NA, Mohamad Ilni
NB, Shun NS, Baohong L, Ya NS and Ying NW: Type 3 diabetes
(Alzheimer's disease): New insight for promising therapeutic
avenues. Panminerva Med. 62:155–163. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang Y, Huang NQ, Yan F, Jin H, Zhou SY,
Shi JS and Jin F: Diabetes mellitus and Alzheimer's disease: GSK-3β
as a potential link. Behav Brain Res. 339:57–65. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Moayedi K, Orandi S, Ebrahimi R, Tanhapour
M, Moradi M, Abbastabar M and Golestani A: A novel approach to type
3 diabetes mechanism: The interplay between noncoding RNAs and
insulin signaling pathway in Alzheimer's disease. J Cell Physiol.
237:2838–2861. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
de la Monte SM: The full spectrum of
Alzheimer's disease is rooted in metabolic derangements that drive
type 3 diabetes. Adv Exp Med Biol. 1128:45–83. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ma LY, Fei YL, Wang XY, Wu SD, Du JH, Zhu
M, Jin L, Li M, Li HL, Zhai JJ, et al: The research on the
relationship of RAGE, LRP-1, and Aβ accumulation in the
hippocampus, prefrontal lobe, and amygdala of STZ-Induced diabetic
rats. J Mol Neurosci. 62:1–10. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
XiaoMing Z, Xi Z, Fang S and Jilin Z:
Specific changes of somatostatin mRNA expression in the frontal
cortex and hippocampus of diabetic rats. J Anat. 204:221–225.
2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lachmann G, Spies C, Windmann V,
Wollersheim T, Engelhardt LJ, Winterer G and Kuehn S: BIOCOG Study
Group. Impact of intraoperative hyperglycemia on brain structures
and volumes. J Neuroimaging. 29:260–267. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Bao H, Liu Y, Zhang M, Chen Z, Zhang W, Ge
Y, Kang D, Gao F and Shen Y: Increased β-site APP cleaving enzyme
1-mediated insulin receptor cleavage in type 2 diabetes mellitus
with cognitive impairment. Alzheimers Dement. 17:1097–1108.
2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Braun M, Ramracheya R and Rorsman P:
Autocrine regulation of insulin secretion. Diabetes Obes Metab. 14
(Suppl 3):S143–S151. 2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Botteri G, Salvadó L, Gumà A, Lee Hamilton
D, Meakin PJ, Montagut G, Ashford MLJ, Ceperuelo-Mallafré V,
Fernández-Veledo S, Vendrell J, et al: The BACE1 product sAPPβ
induces ER stress and inflammation and impairs insulin signaling.
Metabolism. 85:59–75. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wang Q, Duan L, Li X, Wang Y, Guo W, Guan
F and Ma S: Glucose metabolism, neural cell senescence and
Alzheimer's disease. Int J Mol Sci. 23(4351)2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Li H, Yang S, Wu J, Ji L, Zhu L, Cao L,
Huang J, Jiang Q, Wei J, Liu M, et al: cAMP/PKA signaling pathway
contributes to neuronal apoptosis via regulating IDE expression in
a mixed model of type 2 diabetes and Alzheimer's disease. J Cell
Biochem. 119:1616–1626. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Farr SA, Roesler E, Niehoff ML, Roby DA,
McKee A and Morley JE: Metformin improves learning and memory in
the SAMP8 mouse model of Alzheimer's disease. J Alzheimers Dis.
68:1699–1710. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Mishra D, Reddy I and Dey CS: PKCα Isoform
inhibits insulin signaling and aggravates neuronal insulin
resistance. Mol Neurobiol. 60:6642–6659. 2023.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Oriente F, Andreozzi F, Romano C, Perruolo
G, Perfetti A, Fiory F, Miele C, Beguinot F and Formisano P:
Protein kinase C-alpha regulates insulin action and degradation by
interacting with insulin receptor substrate-1 and 14-3-3 epsilon. J
Biol Chem. 280:40642–40649. 2005.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Qi XM and Chen G: p38γ MAPK inflammatory
and metabolic signaling in physiology and disease. Cells.
12(1674)2023.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Esterline R, Oscarsson J and Burns J: A
role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the
treatment of Alzheimer's disease? Int Rev Neurobiol. 155:113–140.
2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Talbot K, Wang HY, Kazi H, Han LY, Bakshi
KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, et
al: Demonstrated brain insulin resistance in Alzheimer's disease
patients is associated with IGF-1 resistance, IRS-1 dysregulation,
and cognitive decline. J Clin Invest. 122:1316–1338.
2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Frith E and Loprinzi PD: Fitness Fatness
Index and Alzheimer-specific mortality. Eur J Intern Med. 42:51–53.
2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Pugazhenthi S, Qin L and Reddy PH: Common
neurodegenerative pathways in obesity, diabetes, and Alzheimer's
disease. Biochim Biophys Acta Mol Basis Dis. 1863:1037–1045.
2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Silva MVF, Loures CMG, Alves LCV, de Souza
LC, Borges KBG and Carvalho MDG: Alzheimer's disease: Risk factors
and potentially protective measures. J Biomed Sci.
26(33)2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Flores-Cordero JA, Pérez-Pérez A,
Jiménez-Cortegana C, Alba G, Flores-Barragán A and Sánchez-Margalet
V: Obesity as a risk factor for dementia and Alzheimer's disease:
The Role of Leptin. Int J Mol Sci. 23(5202)2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Khanna D, Peltzer C, Kahar P and Parmar
MS: Body mass index (BMI): A screening tool analysis. Cureus.
14(e22119)2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Flegal KM, Kit BK, Orpana H and Graubard
BI: Association of all-cause mortality with overweight and obesity
using standard body mass index categories: A systematic review and
meta-analysis. JAMA. 309:71–82. 2013.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Ashwell M, Gunn P and Gibson S:
Waist-to-height ratio is a better screening tool than waist
circumference and BMI for adult cardiometabolic risk factors:
Systematic review and meta-analysis. Obes Rev. 13:275–286.
2012.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Diehl-Wiesenecker E, von Armin CA, Dupuis
L, Müller HP, Ludolph AC and Kassubek J: Adipose tissue
distribution in patients with Alzheimer's disease: A whole body MRI
Case-Control study. J Alzheimers Dis. 48:825–832. 2015.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Boccara E, Golan S and Beeri MS: The
association between regional adiposity, cognitive function, and
dementia-related brain changes: A systematic review. Front Med
(Lausanne). 10(1160426)2023.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Gómez-Apo E, Mondragón-Maya A,
Ferrari-Díaz M and Silva-Pereyra J: Structural Brain Changes
associated with overweight and obesity. J Obes.
2021(6613385)2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Li X, Chen H, Lv Y, Chao HH, Gong L, Li CR
and Cheng H: Diminished gray matter density mediates chemotherapy
dosage-related cognitive impairment in breast cancer patients. Sci
Rep. 8(13801)2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Miao Y, Zhang B, Sun X, Ma X, Fang D,
Zhang W, Wu T, Xu X, Yu C, Hou Y, et al: The presence and severity
of NAFLD are associated with cognitive impairment and hippocampal
damage. J Clin Endocrinol Metab. 108:3239–3249. 2023.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Weinstein G, Zelber-Sagi S, Preis SR,
Beiser AS, DeCarli C, Speliotes EK, Satizabal CL, Vasan RS and
Seshadri S: Association of nonalcoholic fatty liver disease with
lower brain volume in healthy Middle-aged adults in the framingham
study. JAMA Neurol. 75:97–104. 2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Ruchinskas R, Nguyen T, Womack K, Khera A,
Yu FF and Kelley BJ: Diagnostic utility of hippocampal volumetric
data in a memory disorder clinic setting. Cogn Behav Neurol.
35:66–75. 2022.PubMed/NCBI View Article : Google Scholar
|
|
52
|
van Oostveen WM and de Lange ECM: Imaging
techniques in Alzheimer's disease: A review of applications in
early diagnosis and longitudinal monitoring. Int J Mol Sci.
22(2110)2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Prem Kumar A, Singh N, Nair D and Justin
A: Neuronal PET tracers for Alzheimer's disease. Biochem Biophys
Res Commun. 587:58–62. 2022.PubMed/NCBI View Article : Google Scholar
|
|
54
|
So SW, Fleming KM, Nixon JP and Butterick
TA: Early life obesity increases neuroinflammation, amyloid beta
deposition, and cognitive decline in a mouse model of Alzheimer's
disease. Nutrients. 15(2494)2023.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Jayaraman A, Lent-Schochet D and Pike CJ:
Diet-induced obesity and low testosterone increase
neuroinflammation and impair neural function. J Neuroinflammation.
11(162)2014.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Liu P, Wang ZH, Kang SS, Liu X, Xia Y,
Chan CB and Ye K: High-fat diet-induced diabetes couples to
Alzheimer's disease through inflammation-activated C/EBPβ/AEP
pathway. Mol Psychiatry. 27:3396–3409. 2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Medrano-Jiménez E, Jiménez-Ferrer Carrillo
I, Pedraza-Escalona M, Ramírez-Serrano CE, Álvarez-Arellano L,
Cortés-Mendoza J, Herrera-Ruiz M, Jiménez-Ferrer E, Zamilpa A,
Tortoriello J, et al: Malva parviflora extract ameliorates the
deleterious effects of a high fat diet on the cognitive deficit in
a mouse model of Alzheimer's disease by restoring microglial
function via a PPAR-γ-dependent mechanism. J Neuroinflammation.
16(143)2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Zhang B, Chen T, Cao M, Yuan C, Reiter RJ,
Zhao Z, Zhao Y, Chen L, Fan W, Wang X, et al: Gut microbiota
dysbiosis induced by decreasing endogenous melatonin mediates the
pathogenesis of Alzheimer's disease and obesity. Front Immunol.
13(900132)2022.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Obradovic M, Zaric B, Sudar-Milovanovic E,
Ilincic B, Stokic E, Perovic M and Isenovic ER: PCSK9 and
hypercholesterolemia: Therapeutic Approach. Curr Drug Targets.
19:1058–1067. 2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Mannarino MR, Ministrini S and Pirro M:
Nutraceuticals for the treatment of hypercholesterolemia. Eur J
Intern Med. 25:592–599. 2014.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Loera-Valencia R, Goikolea J,
Parrado-Fernandez C, Merino-Serrais P and Maioli S: Alterations in
cholesterol metabolism as a risk factor for developing Alzheimer's
disease: Potential novel targets for treatment. J Steroid Biochem
Mol Biol. 190:104–114. 2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Appleton JP, Scutt P, Sprigg N and Bath
PM: Hypercholesterolaemia and vascular dementia. Clin Sci (Lond).
131:1561–1578. 2017.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Sandebring-Matton A, Goikolea J, Björkhem
I, Paternain L, Kemppainen N, Laatikainen T, Ngandu T, Rinne J,
Soininen H, Cedazo-Minguez A, et al: 27-Hydroxycholesterol,
cognition, and brain imaging markers in the FINGER randomized
controlled trial. Alzheimers Res Ther. 13(56)2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Reiman EM, Chen K, Langbaum JB, Lee W,
Reschke C, Bandy D, Alexander GE and Caselli RJ: Higher serum total
cholesterol levels in late middle age are associated with glucose
hypometabolism in brain regions affected by Alzheimer's disease and
normal aging. Neuroimage. 49:169–176. 2010.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Gottesman RF, Schneider AL, Zhou Y, Coresh
J, Green E, Gupta N, Knopman DS, Mintz A, Rahmim A, Sharrett AR, et
al: Association between midlife vascular risk factors and estimated
brain amyloid deposition. JAMA. 317:1443–1450. 2017.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Serrano-Pozo A, Das S and Hyman BT: APOE
and Alzheimer's disease: Advances in genetics, pathophysiology, and
therapeutic approaches. Lancet Neurol. 20:68–80. 2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Martens YA, Zhao N, Liu CC, Kanekiyo T,
Yang AJ, Goate AM, Holtzman DM and Bu G: ApoE Cascade Hypothesis in
the pathogenesis of Alzheimer's disease and related dementias.
Neuron. 110:1304–1317. 2022.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Raulin AC, Doss SV, Trottier ZA, Ikezu TC,
Bu G and Liu CC: ApoE in Alzheimer's disease: Pathophysiology and
therapeutic strategies. Mol Neurodegener. 17(72)2022.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Koutsodendris N, Nelson MR, Rao A and
Huang Y: Apolipoprotein E and Alzheimer's Disease: Findings,
hypotheses, and potential mechanisms. Annu Rev Pathol. 17:73–99.
2022.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Lanfranco MF, Ng CA and Rebeck GW: ApoE
lipidation as a therapeutic target in Alzheimer's disease. Int J
Mol Sci. 21(6336)2020.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Zhao N, Liu CC, Qiao W and Bu G:
Apolipoprotein E, receptors, and modulation of Alzheimer's disease.
Biol Psychiatry. 83:347–357. 2018.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Fernández-Calle R, Konings SC,
Frontiñán-Rubio J, García-Revilla J, Camprubí-Ferrer L, Svensson M,
Martinson I, Boza-Serrano A, Venero JL, Nielsen HM, et al: APOE in
the bullseye of neurodegenerative diseases: Impact of the APOE
genotype in Alzheimer's disease pathology and brain diseases. Mol
Neurodegener. 17(62)2022.PubMed/NCBI View Article : Google Scholar
|
|
73
|
McNamara DJ: Dietary cholesterol, heart
disease risk and cognitive dissonance. Proc Nutr Soc. 73:161–166.
2014.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Lee SB, Kim HG, Lee JS, Kim WY, Lee MM,
Kim YH, Lee JO, Kim HS and Son CG: Intermittent restraint-induced
sympathetic activation attenuates hepatic steatosis and
inflammation in a high-fat diet-fed mouse model. Am J Physiol
Gastrointest Liver Physiol. 317:G811–G823. 2019.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Ettcheto M, Petrov D, Pedrós I, Alva N,
Carbonell T, Beas-Zarate C, Pallas M, Auladell C, Folch J and
Camins A: Evaluation of neuropathological effects of a High-Fat
diet in a presymptomatic Alzheimer's disease stage in APP/PS1 Mice.
J Alzheimers Dis. 54:233–251. 2016.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Bromley-Brits K, Deng Y and Song W: Morris
water maze test for learning and memory deficits in Alzheimer's
disease model mice. J Vis Exp. 20(2920)2011.PubMed/NCBI View
Article : Google Scholar
|
|
77
|
Song J: Animal model of aluminum-induced
Alzheimer's disease. Adv Exp Med Biol. 1091:113–127.
2018.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Drummond E and Wisniewski T: Alzheimer's
disease: Experimental models and reality. Acta Neuropathol.
133:155–175. 2017.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Zhang L, Chen C, Mak MS, Lu J, Wu Z, Chen
Q, Han Y, Li Y and Pi R: Advance of sporadic Alzheimer's disease
animal models. Med Res Rev. 40:431–458. 2020.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Thawkar BS and Kaur G: Zebrafish as a
promising tool for modeling Neurotoxin-Induced Alzheimer's disease.
Neurotox Res. 39:949–965. 2021.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Tsuda L and Lim YM: Alzheimer's disease
model system using drosophila. Adv Exp Med Biol. 1076:25–40.
2018.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Souder DC, Dreischmeier IA, Smith AB,
Wright S, Martin SA, Sagar MAK, Eliceiri KW, Salamat SM, Bendlin
BB, Colman RJ, et al: Rhesus monkeys as a translational model for
late-onset Alzheimer's disease. Aging Cell.
20(e13374)2021.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Edler MK, Munger EL, Meindl RS, Hopkins
WD, Ely JJ, Erwin JM, Mufson EJ, Hof PR, Sherwood CC and Raghanti
MA: Neuron loss associated with age but not Alzheimer's disease
pathology in the chimpanzee brain. Philos Trans R Soc Lond B Biol
Sci. 375(20190619)2020.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Dewey CW, Davies ES, Xie H and Wakshlag
JJ: Canine cognitive dysfunction: Pathophysiology, diagnosis, and
treatment. Vet Clin North Am Small Anim Pract. 49:477–499.
2019.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Esquerda-Canals G, Montoliu-Gaya L,
Güell-Bosch J and Villegas S: Mouse models of Alzheimer's Disease.
J Alzheimers Dis. 57:1171–1183. 2017.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Puzzo D, Gulisano W, Palmeri A and Arancio
O: Rodent models for Alzheimer's disease drug discovery. Expert
Opin Drug Discov. 10:703–711. 2015.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Hefti F, Dravid A and Hartikka J: Chronic
intraventricular injections of nerve growth factor elevate
hippocampal choline acetyltransferase activity in adult rats with
partial septo-hippocampal lesions. Brain Res. 293:305–311.
1984.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Washida K, Hattori Y and Ihara M: Animal
models of chronic cerebral hypoperfusion: From mouse to primate.
Int J Mol Sci. 20(6176)2019.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Yi J, Liu BY and Cai GX: Study on effect
of Ultra-powder Liuwei Dihuang decoction on recognize and bFGF in
Alzheime's disease rats bFGF. Chin J Exp Tradit Med Formulae.
17:139–142. 2011.
|
|
90
|
Chen HF, Mo YS and Yang C: Protective
effect and mechanism of quercetin on hippocampal neurons in
IBO-injured rats. Tradit Chin Drug Res Clin Pharmacol. 29:552–556.
2018.
|
|
91
|
Lester-Coll N, Rivera EJ, Soscia SJ,
Doiron K, Wands JR and de la Monte SM: Intracerebral Streptozotocin
model of type 3 diabetes: Relevance to sporadic Alzheimer's
disease. J Alzheimers Dis. 9:13–33. 2006.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Wang C, Cai Z, Wang W, Wei M, Si X, Shang
Y, Yang Z, Li T, Guo H and Li S: Piperine regulates glycogen
synthase kinase-3β-related signaling and attenuates cognitive
decline in D-galactose-induced aging mouse model. J Nutr Biochem.
75(108261)2020.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Mustafa HN: Neuro-amelioration of
cinnamaldehyde in aluminum-induced Alzheimer's disease rat model. J
Histotechnol. 43:11–20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Song XY, Hu JF, Chu SF, Zhang Z, Xu S,
Yuan YH, Han N, Liu Y, Niu F, He X and Chen NH: Ginsenoside Rg1
attenuates okadaic acid induced spatial memory impairment by the
GSK3β/tau signaling pathway and the Aβ formation prevention in
rats. Eur J Pharmacol. 710:29–38. 2013.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Haider S, Tabassum S and Perveen T:
Scopolamine-induced greater alterations in neurochemical profile
and increased oxidative stress demonstrated a better model of
dementia: A comparative study. Brain Res Bull. 127:234–247.
2016.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Zangerolamo L, Vettorazzi JF, Solon C,
Bronczek GA, Engel DF, Kurauti MA, Soares GM, Rodrigues KS, Velloso
LA, Boschero AC, et al: The bile acid TUDCA improves glucose
metabolism in streptozotocin-induced Alzheimer's disease mice
model. Mol Cell Endocrinol. 521(111116)2021.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Liu RM: Aging, cellular senescence, and
Alzheimer's Disease. Int J Mol Sci. 23(1989)2022.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Stern Y: Cognitive reserve in ageing and
Alzheimer's disease. Lancet Neurol. 11:1006–1012. 2012.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Leuti A, Fazio D, Fava M, Piccoli A, Oddi
S and Maccarrone M: Bioactive lipids, inflammation and chronic
diseases. Adv Drug Deliv Rev. 159:133–169. 2020.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Kälin S, Heppner FL, Bechmann I, Prinz M,
Tschöp MH and Yi CX: Hypothalamic innate immune reaction in
obesity. Nat Rev Endocrinol. 11:339–351. 2015.PubMed/NCBI View Article : Google Scholar
|
|
101
|
de Git KC and Adan RA: Leptin resistance
in diet-induced obesity: The role of hypothalamic inflammation.
Obes Rev. 16:207–224. 2015.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Boccardi V, Murasecco I and Mecocci P:
Diabetes drugs in the fight against Alzheimer's disease. Ageing Res
Rev. 54(100936)2019.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Kellar D and Craft S: Brain insulin
resistance in Alzheimer's disease and related disorders: Mechanisms
and therapeutic approaches. Lancet Neurol. 19:758–766.
2020.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Campbell JM, Stephenson MD, de Courten B,
Chapman I, Bellman SM and Aromataris E: Metformin use associated
with reduced risk of dementia in patients with diabetes: A
systematic review and Meta-Analysis. J Alzheimers Dis.
65:1225–1236. 2018.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Briggs R, Kennelly SP and O'Neill D: Drug
treatments in Alzheimer's disease. Clin Med (Lond). 16:247–253.
2016.PubMed/NCBI View Article : Google Scholar
|
